Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05949658 · ClinicalTrials.gov registry record · Phase 1
Rapalog Pharmacology (RAP PAC) Study
A Phase 1 study of Aging, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05949658 is a Phase 1 study of Aging that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 72 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05949658, a Phase 1 study of Aging, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of RAP PAC is to identify safe and effective weekly dose(s) for the mTOR inhibitors sirolimus and everolimus that intervene on the underlying fundamental biology of aging. Participants who are 55-89 years old that are free of overt chronic diseases will be assigned to either 6 weeks of sirolimus or everolimus (5 mg, 10 mg, or 15 mg once per week). The investigators will complete the everolimus arm first and then subsequently complete the sirolimus arm of the study. Total time on study would be up to 17 weeks to complete baseline and follow up visits.
Conditions Studied
Interventions
- DRUG Sirolimus
- DRUG Everolimus
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05949658
The ClinicalTrials.gov registry entry for NCT05949658 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 2 interventions - of which Sirolimus is the first listed.
NCT05949658 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05949658 about?
NCT05949658 is a clinical study titled "Rapalog Pharmacology (RAP PAC) Study". The objective of RAP PAC is to identify safe and effective weekly dose(s) for the mTOR inhibitors sirolimus and everolimus that intervene on the underlying fundamental biology of aging. Participants who are 55-89 years old that are free of overt chronic diseases will be assigned to either 6 weeks of...
What is the current status of trial NCT05949658?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2024-05-15. Estimated completion is 2028-12.
What conditions does trial NCT05949658 study?
This clinical trial studies the following conditions: Aging.
What interventions are being tested in trial NCT05949658?
The interventions under investigation include: Sirolimus (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT05949658?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05949658 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
MTOR Inhibitors in Older Adults
RECRUITING · Phase 1
-
Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults
RECRUITING · Phase 1
-
Fisetin to Improve Vascular Function in Older Adults
ACTIVE NOT RECRUITING · Phase 1
-
Wild Blueberries and Cardiovascular Health in Middle-aged/Older Men and Postmenopausal Women
ACTIVE NOT RECRUITING · Phase 1
-
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.